Search Within

Emily Ann Carbone

Formats
  1. Meeting Abstract (18)
  2. Journal Article (9)
Groups
  1. Department of Medicine (27)
  2. Genitourinary Oncology Service (27)
  3. Solid Tumor Oncology Division (27)
  4. Hematology-Oncology Fellows (12)
  5. Epidemiology and Biostatistics (9)
  6. GSK Faculty (9)

More Groups

People
  1. Howard Scher (27)
  2. Ethan Barnett (23)
  3. Melanie Hullings (10)
  4. Michael Morris (8)
  5. Daniel Danila (7)
  6. Jimmy Zhao (7)

More People

Years
  1. 2023 (3)
  2. 2022 (4)
  3. 2021 (6)
  4. 2020 (6)
  5. 2019 (4)
  6. 2018 (2)

More Years

Publications
  1. Journal of Clinical Oncology (14)
  2. Cancer Research (3)
  3. Annals of Oncology (2)
  4. Clinical Cancer Research (2)
  5. European Urology (2)
  6. European Journal of Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (14)
  2. American Association for Cancer Research (5)
  3. Elsevier Science, Inc. (2)
  4. Oxford University Press (2)
  5. American Medical Association (1)
  6. Elsevier Inc. (1)

More Publishers

Results (27)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide
    Journal Article

    Brown, L. C.; Halabi, S.; Schonhoft, J. D.; Yang, Q.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Barnett, E. S.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Scher, H. I.; Armstrong, A. J.; Schonhoft, J. D.; Gill, A.; Zhao, J.; Barnett, E.; Carbone, E.; Lu, J.; Antonarakis, E. S.; Luo, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Armstrong, A. J.; Schonhoft, J. D.; Gill, A.; Zhao, J. L.; Barnett, E.; Carbone, E.; Lu, J.; Antonarakis, E. S.; Luo, J.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer
    Journal Article

    Lu, D.; Krupa, R.; Harvey, M.; Graf, R. P.; Schreiber, N.; Barnett, E.; Carbone, E.; Jendrisak, A.; Gill, A.; Orr, S.; more...
    Journal of Circulating Biomarkers (2020)

    Fulltext@MSK | Save
  • Morphology-predicted large-scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer
    Journal Article

    Schonhoft, J. D.; Zhao, J. L.; Jendrisak, A.; Carbone, E. A.; Barnett, E. S.; Hullings, M. A.; Gill, A.; Sutton, R.; Lee, J.; Dago, A. E.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane
    Meeting Abstract

    Scher, H. I.; Jendrisak, A.; Gill, A.; Barnett, E.; Gopalan, A.; Zaidi, S.; Benoliel, H.; Carbone, E.; Byun, J.; Schonhoft, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi)
    Meeting Abstract

    Schonhoft, J.; Gill, A.; Graf, R. P.; Jendrisak, A.; Barnett, E.; Benoliel, H.; Carbone, E.; Tubbs, A.; Orr, S.; Byun, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Wibmer, A. G.; Haywood, S.; Weg, E. S.; Barnett, E. S.; Kim, C. J.; Carbone, E. A.; Vasselman, S. E.; Nguyen, B.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Clinical utility of the nuclear-localized AR-V7 biomarker in circulating tumor cells in improving physician treatment choice in castration-resistant prostate cancer
    Journal Article

    Graf, R. P.; Hullings, M.; Barnett, E. S.; Carbone, E.; Dittamore, R.; Scher, H. I.
    European Urology (2020)

    Fulltext@MSK | Save
  • CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts)
    Meeting Abstract

    Scher, H. I.; Lee, J.; Dago, A. E.; Barnett, E.; Sutton, R.; Carbone, E.; Schreiber, N. A.; Hullings, M.; Ebrahim, N.; Landers, M. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save